Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The proportion of HCV infected patients over age 65 years in Western countries is increasing.
This growth and the advent of new antiviral therapy bring into the question the real world
efficacy and safety of the combination of Sofosbuvir and Simeprevir (SOF/SMV) plus a flat
dose of ribavirin (RBV) in elderly patients compared to younger patients.